Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $5.01. The company has a market cap of $366.98 million, a price-to-earnings ratio of -0.82 and a beta of 1.92.

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a ...

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...

PACB stock opened at $1.56 on Tuesday. Pacific Biosciences of California has a 12-month low of $1.16 and a 12-month high of $6.09. The company has a quick ratio of 8.64, a current ratio of 9.74 ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a significant ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51 ...

Pacific Biosciences' Q4'24 results were another disappointment, with revenue and margin misses, and 2025 guidance was notably below expectations. Underlying utilization growth (genetic data ...

SUGAR LAND, Texas--(BUSINESS WIRE)--FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if ...